Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. (KYTX) priced its initial public offering on Feb 8, 2024 at $22.00 per share, raising $319M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $898.1M. J.P. Morgan was lead-left underwriter, joined by Morgan Stanley, Leerink Partners and Wells Fargo. Paul Hastings advised the company and Covington & Burling advised the underwriters.

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases. Its lead candidate, KYV-101, is an autologous CD19 CAR T-cell therapy being developed across rheumatology and neurology indications.

Status

IPO

Ticker

KYTX

Exchange

Nasdaq Global Select

Priced

Feb 8, 2024

IPO price

$22.00

Raised

$319M

Market cap at IPO price

$898.1M

First filed

Jan 16, 2024

Underwriters

J.P. Morgan, Morgan Stanley, Leerink Partners and Wells Fargo

Company counsel

Paul Hastings

Underwriters' counsel

Covington & Burling

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.